Is Actinium Pharmaceuticals, Inc. (ATNM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.2% / 30% | 194.7% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 4.2% / 33% | 194.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 2.0% / 33% | 94.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 4.2% / 33% | 194.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 2.0% / 33% | 94.8% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -6324.4% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -133.1% | |
| Return on Assets (ROA) | -33.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$33M |
| Free Cash Flow | -$33M |
| Total Debt | $2M |
| Debt-to-Equity | 8.3 |
| Current Ratio | 8.0 |
| Total Assets | $77M |
Price & Trading
| Last Close | $1.05 |
| 50-Day MA | $1.16 |
| 200-Day MA | $1.44 |
| Avg Volume | 119K |
| Beta | -0.3 |
|
52-Week Range
$1.01
| |
About Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Actinium Pharmaceuticals, Inc. (ATNM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Actinium Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Actinium Pharmaceuticals, Inc.'s debt ratio?
Actinium Pharmaceuticals, Inc.'s debt ratio is 4.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.0%.
What are Actinium Pharmaceuticals, Inc.'s key financial metrics?
Actinium Pharmaceuticals, Inc. has a market capitalization of $32M. Return on equity stands at -133.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.